ArticleAnnals of hematology2025
Pediatric bone marrow microenvironment before and after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study comparing donors and recipients.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To compare the bone marrow microenvironment between healthy children and adults and investigate the association between the posttransplant bone marrow microenvironment and PGF in pediatric HSCT recipients. This retrospective study involved pediatric patients who underwent allogeneic-HSCT at Beijing Children's Hospital and Baoding Children's Hospital between January 2021 and June 2024. Bone marrow samples were collected before HSCT and between Days 14 and 90 post-HSCT to measure the percentages of endothelial progenitor cells (EPCs) and hematopoietic stem cells (CD34 + HSCs), as well as reactive oxygen species (ROS) levels. Selected donors were enrolled as controls, and their bone marrow samples were similarly assessed for those parameters. One hundred forty pediatric patients and 48 bone marrow donors were included in this study. Subsequent analysis revealed that adult donors had a significantly lower proportion of HSCs compared with the 0-6-year donors subgroup (0.865% (0.03, 2.21) vs. 3.38% (1.38, 5.23); U = 3.93, P < 0.001) and significantly higher HSC-ROS levels (1,979 (1,039, 5,166) vs. 977 (453, 1,597); U = 3.11, P = 0.002). The good graft function (GGF) group had a significantly greater proportion of EPCs compared with the poor graft function (PGF) group (0.106% (0.03-0.69) vs. 0.047%(0.015-0.09), U = 3.184, P = 0.001). Receiver operating characteristic (ROC) analysis revealed that an EPC proportion threshold > 0.071% in the bone marrow at 14-90 days post-transplantation predicted GGF outcomes (AUC = 0.874; 95% CI: 0.743-1.000). These findings suggest that compared with their adult counterparts, pediatric bone marrow niches possess superior hematopoietic regenerative capacity and reduced oxidative stress and that a lower proportion of EPCs is responsible for defective hematopoiesis in PGF pediatric patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.